IMMUNOLOGIC EVALUATIONS OF HIV-INFECTED PREGNANT WOMEN ON HAART

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究将解决以下有关HIV感染孕妇的免疫保存和/或重建的问题：1)接受HAART治疗的HIV感染孕妇的免疫反应与未感染孕妇的免疫反应是否有足够的差异，从而证明对这类患者采取特殊免疫和/或其他预防策略是合理的？2)分娩后停止HAART对HIV感染妇女的免疫反应造成的损失是多少？为了解决第一个问题，我们将比较接受HAART治疗的40名感染艾滋病毒的孕妇和10名未感染的孕妇的念珠菌特异性细胞介导免疫和对流感疫苗的反应。第二个问题将通过测量怀孕期间和分娩后第一年的艾滋病毒特异性和抗微生物免疫来解决。这两个比较中的任何一个的显著差异将表明HAART不应在这种情况下停止，我们需要修改我们目前对感染艾滋病毒的孕妇的管理。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will address the following questions regarding immune preservation and/or reconstitution of HIV-infected pregnant women: 1) Do immune responses of HIV-infected pregnant women on HAART differ enough from those of uninfected pregnant women to justify special immunization and/or other prophylactic strategies for this group of patients? 2) What is the toll of stopping HAART after delivery on the immune responses of HIV-infected women? To address the first question, we will compare Candida-specific cell-mediated immunity and responses to influenza vaccine among 40 HIV-infected pregnant women on HAART vs. 10 uninfected pregnant controls. The second question will be tackled by measuring HIV-specific and anti-microbial immunity during pregnancy and the first year after delivery. Significant differences in either of these comparisons will indicate that HAART should not be stopped in this setting and that we need to revise our current management of HIV-infected pregnant women.